Novo Nordisk stock has fallen roughly 19% from the start of 2026 through the close on November 9, and its latest earnings report is now testing whether the Danish drugmaker can restart its momentum in the weight-loss market. The answer isn't clean. One part of the business is accelerating. Another is shrinking.

Here's what the numbers say.

What went right in the quarter?

Sales of the Wegovy pill exceeded market expectations in the most recent quarter, and the company raised its outlook for the year. That's the decision that matters for investors: management saw enough demand to lift guidance, not merely to hold it.

The market's core question is straightforward. Can the pill expand the patient base and help Novo strengthen its position against Eli Lilly, its main rival in obesity drugs? A pill is easier to take than an injection, so it can reach patients who would never touch a needle. That's the strategic logic behind the optimism.

What's still going wrong?

Plenty. Sales of injectable Wegovy in the U.S. declined, and competition from Eli Lilly remains strong. The two problems feed each other, because Lilly is winning share in the same injectable segment where Novo built its franchise.

And there's a caveat on the guidance itself. Even after raising its outlook, Novo still does not necessarily expect growth this year, according to the report. Translation: the raise reflects a less-bad year, not necessarily a growing one. The quarter is an encouraging sign, not proof that the difficulties are behind the company.

The uneven picture in brief:

• Wegovy pill sales: beat market expectations in the latest quarter
• Full-year outlook: raised by the company
• U.S. injectable Wegovy: sales declined
• Eli Lilly competition: still strong
• Expected 2026 growth: not guaranteed despite the raise

Where does the stock stand technically?

NVO trades around $41. That puts it slightly above the 50-day exponential moving average (a trend line weighting recent prices more heavily), which traders read as short-term stabilization.

But it still sits below the 200-day simple moving average, which sits around $44. That longer-term line is the one that defines whether a stock is in recovery or just bouncing. Novo hasn't cleared it.

So the technical picture mirrors the fundamental one: short-term improvement, long-term damage not yet repaired.

Who is Novo Nordisk, in brief?

Novo Nordisk is a Danish pharmaceutical company that develops and manufactures medicines for diabetes and obesity, including Ozempic and Wegovy. Its roots go back to 1923, and it took its current form in 1989 after a merger. The company is headquartered in Bagsværd, Denmark, and its U.S.-listed shares trade on the New York Stock Exchange under the ticker NVO.

Can the pill carry the turnaround?

That's the open question, and the report itself frames it: will Novo be able to turn demand for the weight-loss pill into steady growth and strengthen its position against Eli Lilly again, or will weakness in injectables and competition continue to pressure the stock?

The pieces are genuinely in tension. A successful pill launch widens the addressable market and offers differentiation against Lilly. Declining U.S. injectable sales undercut the installed base that funded the whole franchise. Which force wins out determines whether the roughly 19% year-to-date decline was a bottom or a waypoint.

Time will tell. The next few quarters of pill sales, and the trajectory of U.S. injections, will answer it.

Trading in financial instruments involves a high level of risk and may not be suitable for all investors. Past performance is not indicative of future results.